- Low-dose aspirin for cardioprotection (per local applicable guidelines) and low-dose LMWH are permitted (in subjects who are on a stable dose of LMWH for at least 6 weeks before the first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor).